Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. (VTVT) is a clinical-stage biopharmaceutical company pioneering oral small molecule therapies for chronic diseases, including type 1 diabetes and inflammatory disorders. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access consolidated news about cadisegliatin (TTP399) advancements, partnership announcements, and financial reports. Stay informed on critical updates including trial results, FDA communications, and strategic collaborations that shape the company’s trajectory.
All content is sourced directly from official releases and verified financial filings. Bookmark this page for streamlined access to material events affecting investment decisions and therapeutic innovation in metabolic disease research.
Cantex Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to its drug azeliragon for treating pancreatic cancer. This designation follows a similar status received for treating glioblastoma in 2023. The designation offers benefits like seven years of marketing exclusivity, tax credits, and fee exemptions. Cantex is conducting a clinical trial to study azeliragon's efficacy on metastatic pancreatic cancer patients in top U.S. cancer centers. CEO Stephen G. Marcus emphasized the urgent need for new treatments for advanced pancreatic cancer and other cancers, enhancing their commitment to innovative therapies.
vTv Therapeutics Inc. reported its 2024 first-quarter financial results, showcasing significant milestones and corporate updates. The company's cash position grew to $52.3 million, thanks to a successful private placement, funding future Phase 3 studies for cadisegliatin. The submission of the Phase 3 trial protocol to the FDA marks a pivotal step towards developing adjunctive therapy for type 1 diabetes. Financially, R&D expenses decreased, while G&A expenses increased slightly. The company reported a net loss of $4.9 million for the quarter.
FAQ
What is the current stock price of Vtv Therapeutics (VTVT)?
What is the market cap of Vtv Therapeutics (VTVT)?
